Company intelligence / Profile preview

Alexza Pharmaceuticals

Fremont, California, United Statesfacebook.com ↗

Ownership: Private
Development stage: Other

Overview

Adasuve, the lead product using Staccato technology, is approved and marketed for acute agitation in adults with schizophrenia or bipolar I disorder. Other programs using the same platform are at various stages of development targeting neurological and pain indications.

Therapeutic areas: PsychiatryGastroenterologyNeurologyOncology
Modalities: Small moleculeInhaled drug delivery system ("Staccato" technology)Device (hand-held inhaler platform)
Industry: Biotech

Partnerships

Parent company integration with Ferrer Therapeutics/Ferrer US

Beyond the preview

Go deeper on Alexza Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alexza Pharmaceuticals.

Explore the full profile